Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

1.3K

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Davide Amore1, Ylenia Pecoraro1, Carolina Carillo1

  • 1Division of Thoracic Surgery and Lung Transplant, Sapienza University of Rome, AOU Policlinico Umberto I, Rome, Italy.

Transplantation Proceedings
|March 27, 2020
PubMed
Abstract

Insights

New antibiotics ceftazidime-avibactam (CEF-AVI) and ceftazidime-tazobactam (CEFT-TAZ) show promise for treating multidrug-resistant (MDR) bacterial infections like Klebsiella pneumoniae and Pseudomonas aeruginosa following lung transplantation (LTx). These treatments appear effective with no observed side effects.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Lung transplantation (LTx) recipients are susceptible to challenging multidrug-resistant (MDR) bacterial infections.
  • Effective treatment options for MDR infections post-LTx are crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of ceftazidime-avibactam (CEF-AVI) and ceftazidime-tazobactam (CEFT-TAZ) in treating MDR Klebsiella pneumoniae and Pseudomonas aeruginosa infections.
  • To assess the safety and outcomes of these antibiotic regimens in lung transplant recipients.

Main Methods:

  • Retrospective case series describing the treatment of 7 lung transplant patients with MDR K. pneumoniae and P. aeruginosa infections.
  • Patients received either CEFT-TAZ for P. aeruginosa (average 10 days) or CEF-AVI for K. pneumoniae (average 14 days).
  • Clinical data including respiratory function, inflammatory markers, and treatment outcomes were analyzed.

Main Results:

  • All patients presented with respiratory compromise and elevated inflammatory markers.
  • CEFT-TAZ and CEF-AVI treatments were administered for an average of 10 and 14 days, respectively.
  • No adverse drug reactions were reported; one patient died from primary graft dysfunction unrelated to treatment.

Conclusions:

  • Ceftazidime-avibactam and ceftazidime-tazobactam appear to be effective and safe options for MDR bacterial infections post-lung transplantation.
  • These novel antibiotic combinations offer a potential therapeutic strategy against challenging pathogens in immunocompromised patients.

More Related Videos

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation07:28

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation

Published on: October 11, 2024

624
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation10:01

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Published on: July 10, 2012

21.0K

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
434
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
675
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
480
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.8K
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
459
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
762